PharmaSGP Holding Sustains Profitable Growth Streak into Q3 2023

• PharmaSGP Holding SE continues profitable growth in Q3 2023, with quarterly revenues of €26.0 million, exceeding the figures for the two previous quarters of the year.
• The company generated revenues of €75.7 million in the first nine months of 2023, representing a growth of 18.3% compared to the previous year's figure of €63.9 million.
• Adjusted EBITDA for the 2023 reporting period was €24.7 million, a year-on-year growth of 21.3%, and the adjusted EBITDA margin rose to 32.7%.
• The Management Board of PharmaSGP expects revenues of between €95 million and €100 million for the full year 2023, with adjusted EBITDA expected to be between €30 million and €34 million.
• PharmaSGP will publish its full nine-months report on November 28, 2023.
• The company plans to further expand its competitive position by increasing the number of indications covered by its product offering, increasing its European footprint, and accelerating its growth strategy through selected M&A opportunities.

The price of PharmaSGP Holding at the time of the news was 20,650EUR and did not change compared to the previous day.
43 minutes after the article was published, the price was 20,600EUR this corresponds to a minus of -0,24 % since publication.

PharmaSGP Holding

+1,33 %

+2,23 %

+5,53 %

+2,23 %

-19,65 %

+37,54 %

-33,62 %

ISIN:DE000A2P4LJ5WKN:A2P4LJ

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• Max